Skip to main content
. 2018 Jan 29;5(1):e000150. doi: 10.1136/bmjgast-2017-000150

Figure 1.

Figure 1

Flow of patients through the trial. CD, coeliac disease; DGP, deamidated gliadin peptide; EMA IgA, endomysial antibody IgA; GIT, gastrointestinal disorders; HLA, human leukocyte antigen; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; TE, transient elastography; TTGA, tissue transglutaminase antibody.